Amy D Klion

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Eosinophilic myeloproliferative disorders
    Amy D Klion
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hematology Am Soc Hematol Educ Program 2011:257-63. 2011
  2. ncbi request reprint Familial eosinophilia: a benign disorder?
    Amy D Klion
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:4050-5. 2004
  3. pmc How I treat hypereosinophilic syndromes
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 114:3736-41. 2009
  4. ncbi request reprint Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 117:1292-302. 2006
  5. ncbi request reprint Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:2939-41. 2004
  6. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
  7. pmc Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy
    Princess U Ogbogu
    National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 124:1319-25.e3. 2009
  8. ncbi request reprint Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
  9. ncbi request reprint Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
    Amy D Klion
    Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
    Blood 103:473-8. 2004
  10. ncbi request reprint Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome
    Yae Jean Kim
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Hematol 82:615-24. 2007

Detail Information

Publications33

  1. pmc Eosinophilic myeloproliferative disorders
    Amy D Klion
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hematology Am Soc Hematol Educ Program 2011:257-63. 2011
    ....
  2. ncbi request reprint Familial eosinophilia: a benign disorder?
    Amy D Klion
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:4050-5. 2004
    ..These data suggest that, despite prolonged marked eosinophilia, FE can be distinguished from HES by a more benign clinical course that may be related to a relative lack of eosinophil activation...
  3. pmc How I treat hypereosinophilic syndromes
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 114:3736-41. 2009
    ..5 x 10(9)/L (1500/mm3) or higher and discusses the role of currently available therapeutic agents in the treatment of these patients...
  4. ncbi request reprint Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 117:1292-302. 2006
    ..Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized...
  5. ncbi request reprint Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:2939-41. 2004
    ..These data suggest that anti-IL-5 therapy may be useful in the treatment of HES irrespective of the underlying etiology, although the observed rebound eosinophilia and attenuation of response require further study...
  6. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
    ..This trial was registered at http://www.clinicaltrials.gov as no. NCT00044304...
  7. pmc Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy
    Princess U Ogbogu
    National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 124:1319-25.e3. 2009
    ..With the exception of a recent multicenter trial of mepolizumab (anti-IL-5 mAb), published therapeutic experience has been restricted to case reports and small case series...
  8. ncbi request reprint Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
    ..These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear...
  9. ncbi request reprint Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
    Amy D Klion
    Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
    Blood 103:473-8. 2004
    ..The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES...
  10. ncbi request reprint Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome
    Yae Jean Kim
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Hematol 82:615-24. 2007
    ..Eosinophilia defines a distinct subgroup of ALPS patients with increased serum IgE levels, increased numbers of PBL of multiple lineages, and higher mortality from infectious complications...
  11. ncbi request reprint Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
    Yae Jean Kim
    NIAID, NIH, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 114:1449-55. 2004
    ....
  12. ncbi request reprint KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    Irina Maric
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:680-7. 2007
    ..It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment...
  13. pmc Marked and persistent eosinophilia in the absence of clinical manifestations
    Yun Yun K Chen
    Eosinophil Pathology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Frederick, MD
    J Allergy Clin Immunol 133:1195-202. 2014
    ....
  14. pmc IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    J Allergy Clin Immunol 128:1086-92.e1-3. 2011
    ..Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo...
  15. pmc Molecular identification of Wolbachia from the filarial nematode Mansonella perstans
    Paul B Keiser
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Biochem Parasitol 160:123-8. 2008
    ....
  16. ncbi request reprint Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:4660-6. 2003
    ..In summary, elevated serum tryptase appears to be a sensitive marker of a myeloproliferative variant of HES that is characterized by tissue fibrosis, poor prognosis, and imatinib responsiveness...
  17. pmc Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria-malaria co-infection
    Simon Metenou
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Eur J Immunol 42:641-50. 2012
    ....
  18. pmc Filariasis in travelers presenting to the GeoSentinel Surveillance Network
    Ettie M Lipner
    Office of Global Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Negl Trop Dis 1:e88. 2007
    ..The GeoSentinel Surveillance Network, a global network of medicine/travel clinics, was established in 1995 to detect morbidity trends among travelers...
  19. pmc KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells
    Eunice Ching Chan
    Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA
    Exp Hematol 41:870-881.e2. 2013
    ..These data suggest that neoplastic mast cells favor a GNNK(-) variant predominance, which in turn enhances the activating potential of the KIT D816V mutation and thus could influence therapeutic sensitivity in systemic mastocytosis. ..
  20. ncbi request reprint Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans
    Paul B Keiser
    Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0425, USA
    Am J Trop Med Hyg 69:331-5. 2003
    ..bancrofti infection in this community, and that acute post-treatment reactions should not limit patient compliance in community-based programs to eliminate lymphatic filariasis...
  21. ncbi request reprint Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 187:128-33. 2003
    ..IgG4 antibodies to recombinant Ll-SXP-1 are a highly specific marker of L. loa infection and may be useful for the diagnostic evaluation of persons with filariasis of unclear etiology...
  22. ncbi request reprint Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection
    Simon Metenou
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Eur J Immunol 44:2036-47. 2014
    ....
  23. ncbi request reprint The role of eosinophils in host defense against helminth parasites
    Amy D Klion
    Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0425, USA
    J Allergy Clin Immunol 113:30-7. 2004
    ..This article will provide an overview of our current knowledge about eosinophils and their role, both protective and pathogenetic, in parasitic helminth infections...
  24. pmc Rapid, novel, specific, high-throughput assay for diagnosis of Loa loa infection
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, 4 Center Drive, Bethesda, Maryland 20892, USA
    J Clin Microbiol 46:2298-304. 2008
    ..These results suggest that LIPS (and the even more rapid test QLIPS) represents a major advance in the ability to diagnose L. loa infection and may have future applications for point-of-care diagnostics...
  25. pmc Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections
    Sasisekhar Bennuru
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Trop Med Hyg 83:884-90. 2010
    ....
  26. ncbi request reprint Eosinophils in vasculitis: characteristics and roles in pathogenesis
    Paneez Khoury
    Laboratory of Parasitic Diseases, National Institutes of Allergic and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Nat Rev Rheumatol 10:474-83. 2014
    ..This Review focuses on the aspects of eosinophil biology most relevant to the pathogenesis of vasculitis and provides an update of current knowledge regarding the role of eosinophils in EGPA and other vasculitides. ..
  27. pmc Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection
    Kawsar R Talaat
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pediatr Blood Cancer 53:1120-3. 2009
    ..Thus, loss of SAP function can lead to dysregulated immune responses characterized by the uncontrolled expansion and activation of T cells independent of EBV infection...
  28. ncbi request reprint Approach to the therapy of hypereosinophilic syndromes
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 4, Rm 126, 4 Center Drive, Bethesda, MD 20892, USA
    Immunol Allergy Clin North Am 27:551-60. 2007
    ..This article discusses current treatment modalities for myeloproliferative HES, idiopathic HES, and lymphocytic-variant HES...
  29. pmc Filaria-induced monocyte dysfunction and its reversal following treatment
    Roshanak Tolouei Semnani
    Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, 4 Center Drive, Room 4 126, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 74:4409-17. 2006
    ..These data suggest that the function and gene expression of monocytes in filaria-infected patients are altered but that this dysfunction is partially reversible following antifilarial treatment...
  30. ncbi request reprint Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome
    Richard M Stone
    Adult Leukemia Program, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 31:12-7. 2004
    ..The efficacy of relatively low imatinib concentrations in HES, mediated by inhibition of FIP1L1-PDGFRalpha kinase activity, causally implicates FIP1L1-PDGFRA in the pathogenesis in certain HES patients...
  31. ncbi request reprint Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome
    A Barry Kay
    Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Guy Scadding Building, Dovehouse Street, London, SW3 6LY UK
    Immunol Allergy Clin North Am 24:645-66, vii. 2004
    ..This article discusses the rationale for the use of anti-IL-5 therapy in asthma and hypereosinophilic syndrome and summarizes the available clinical data on the use of anti-IL-5 to treat these disorders...
  32. doi request reprint Treatment of patients with the hypereosinophilic syndrome with mepolizumab
    Marc E Rothenberg
    Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    N Engl J Med 358:1215-28. 2008
    ..Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity...
  33. pmc Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease
    Cindy S Ma
    Lymphocyte Differentiation Laboratory, Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
    J Clin Invest 116:322-33. 2006
    ..Production of affinity-matured IgM by IgMCD27 B cells may protect against pathogens to which a normal immune response is elicited in XLP patients...